In addition to the in vivo data on the NKG2DL+ benign cells, NKG2DL high expressing glioma cells [16] and breast cancer stem cells [17] were found to be killed by allogeneic NKG2D+ NK cell in vitro. This evidence concerns the gene KLRK1 and glioma.